Abstract
Resistance to the current first-line antimalarials threatens the control of malaria caused by the protozoan parasite Plasmodium falciparum and underscores the urgent need for new drugs with novel modes of action. Here, we present the argument that the parasite’s chloroquine resistance transporter (PfCRT) constitutes a promising target to combat multidrug-resistant malaria.